3-(Diethylamino)-2-phenyl-1-propen | 22500-26-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(Diethylamino)-2-phenyl-1-propen
• 英文别名: N,N-diethyl-2-phenylprop-2-en-1-amine；α-Diethylaminomethylstyrol；diethyl-(2-phenyl-allyl)-amine；Diaethyl-(2-phenyl-allyl)-amin；3-Diaethylamino-2-phenyl-propen-(1)
• CAS: 22500-26-1
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: APBYIIKZLQOKFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-氯丙-1-烯-2-基苯 、 二乙胺 在 copper(II) bis(trifluoromethanesulfonate) 、 三乙胺 作用下， 以 水 为溶剂， 反应 12.0h， 以98%的产率得到3-(Diethylamino)-2-phenyl-1-propen
  参考文献：
  名称：

  铜（II）催化水中的萜烯氯化物的烯丙基胺化

  摘要：

  已经开发出一种高效的方法，该方法通过廉价的铜（II）作为催化剂在水中从三氯化碳合成烯丙基胺。在仲胺存在下，在温和的条件下，烯丙基氯以高的区域选择性反应，以优异的收率得到N-烯丙基胺。

  DOI：

  10.1016/j.catcom.2011.12.019

文献信息

• Stannylated allyl carbonates as versatile building blocks for the diversity oriented synthesis of allylic amines and amides
  作者：Christian Bukovec、Uli Kazmaier

  DOI：10.1039/c0ob00945h

  日期：——

  Stannylated allylic carbonates are suitable substrates for Pd-catalyzed allylic aminations. In DMF and with [allylPdCl]2 as catalyst the stannylated allyl amines formed can be directly coupled with electrophiles according to the Stille protocol, giving rise to highly functionalized buiding blocks in excellent yields.

  钯催化的烯丙基胺化反应适用于锡烯丙基碳酸酯作为底物。在DMF中，以[allylPdCl]2为催化剂，所生成的锡烯丙基胺可直接依据Stille偶联协议与亲电试剂反应，高效获得功能化的构建单元，收率极佳。
• Copper-Catalyzed Decarboxylative Functionalization of Conjugated β,γ-Unsaturated Carboxylic Acids
  作者：Wei Zhang、Chengming Wang、Qiu Wang

  DOI：10.1021/acscatal.0c03621

  日期：2020.11.20

  Copper-catalyzed decarboxylative coupling reactions of conjugated β,γ-unsaturated carboxylic acids have been achieved for allylic amination, alkylation, sulfonylation, and phosphinoylation. This approach was effective for a broad scope of amino, alkyl, sulfonyl, and phosphinoyl radical precursors as well as various conjugated β,γ-unsaturated carboxylic acids. These reactions also feature high regioselectivity

  铜催化的共轭 β,γ-不饱和羧酸的脱羧偶联反应已用于烯丙基胺化、烷基化、磺酰化和膦酰化。这种方法对广泛的氨基、烷基、磺酰基和膦酰基自由基前体以及各种共轭 β,γ-不饱和羧酸有效。这些反应还具有区域选择性高、官能团耐受性好、操作简单等特点。机理研究表明，该反应通过铜催化亲电加成到烯烃上，然后脱羧而进行，其中涉及自由基中间体。这些见解提出了一种模块化和强大的策略，可以从容易获得且稳定的羧酸中获取多功能功能化的含烯丙基骨架。
• Anti-Markovnikov rearrangement in sulfur mediated allylic C–H amination of olefins
  作者：Zhong Zhang、Hongguang Du、Jiaxi Xu、Pingfan Li

  DOI：10.1039/c6cc05128f

  日期：——

  Hitherto unknown chemistry involving anti-Markovnikov rearrangement from secondary carbocations toward primary carbocations or primary triflates was discovered.

  迄今尚未发现涉及从次级碳正离子向初级碳正离子或初级三氟甲磺酸酯的反马尔科夫尼科夫重排的未知化学。
• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：AMGEN INC

  公开号：WO2014152236A1

  公开（公告）日：2014-09-25

  Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.

  提供了奥米卡替夫美卡比尔的某些药物配方以及其制备和使用方法。
• Process for producing an oral sustained-release preparation of fasudil hydrochloride
  申请人：ASAHI KASEI PHARMA CORPORATION

  公开号：US20040131679A1

  公开（公告）日：2004-07-08

  Disclosed is an oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof, the preparation comprising at least one sustained-release coated particle comprising a core having a surface and a coating formed on the surface of the core, wherein the core contains the active ingredient and the coating comprises a coating base material and a specific insoluble auxiliary material, and wherein the preparation exhibits, with respect to the active ingredient, a specific dissolution rate, as measured by the dissolution test. By using the oral sustained-release preparation of the present invention, it becomes possible to surely control the release of fasudil hydrochloride from the preparation, so that the effect of the active ingredient is maintained for a long period of time. Therefore, the burden of the patient who has to take the preparation can be decreased and the compliance with respect to the administration of the preparation can be improved. Also disclosed is a method for evaluating an oral sustained-release preparation containing the active ingredient, wherein the evaluation is conducted with respect to the sustained-release ability of the active ingredient.

  本发明公开了一种口服缓释制剂，其含有从羟氯喹硫酸盐和其水合物组成的群中选择的至少一种活性成分，该制剂包括至少一种缓释包被粒子，其包括具有表面的核心和形成在核心表面上的涂层，其中核心含有活性成分，涂层包括涂层基材料和特定的不溶性辅助材料，且该制剂展现出特定的溶解速率，如溶解测试所测量的。通过使用本发明的口服缓释制剂，可以确保控制羟氯喹硫酸盐的释放，从而使活性成分的效果持续较长时间。因此，可以减轻服用制剂的患者的负担，并提高对制剂的管理的遵从性。还公开了一种评估口服缓释制剂的方法，该方法与活性成分的缓释能力有关。